A 685-patient, 33-site trial published in the journal CHEST found Integrated Diagnostics' Xpresys Lung 2 test, also known as XL2, can detect early-stage cancer indicators LG3BP and C163A blood plasma proteins in 8mm to 30mm lung nodules. The test, which allows protein measurement to be combined with five standard-of-care clinical factors into a single risk assessment, demonstrated an error rate of 3%, compared with the 45% misclassification of cancers in standard of care.
Study shows positive results for Integrated Diagnostics' lung cancer test
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.